Gilead Sciences, Inc. · Drug Manufacturers - General

GILDGilead Sciences, Inc.

Reports 2026-10-22 · ThuReaction day 10-23upcoming

Before the print · expectationsupdated nightly until T-1

Expected move (options)±4.3%from the event straddle
Actual vs expected, last 8Q—Lite and up
Short interest—Lite and up
Lean—Lite and up

Lean, evidence and peer references — Lite

The calendar is free. From the entry plan up you also get, for every ≥$1B reporter: the model lean with the evidence behind it, the peers that have already reported and how they traded, and the stock's own earnings history.

  • Lean and confidence, with the evidence rows that produced it
  • Per-peer reference table: each peer's own print, move and guidance
  • Expected-move band and the stock's last eight prints
Sign in / start free

The print · 8-K and callupcoming · 2026-10-22

Revenue—
est. $7.94B
EPS—
est. $2.22
Guidance—read from the 8-K once filed

Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →